ACUTE KIDNEY INJURY: Clinical trials in AKI: is the end in sight?

    loading  Checking for direct PDF access through Ovid


Clinical trials in patients with acute kidney injury (AKI) have been stymied by a lack of consensus on suitable renal-specific end points. In a recent analysis, Grams et al. suggest that a sustained 30–40% reduction in estimated glomerular filtration rate after hospital discharge might be a suitable intermediate end point for AKI clinical trials.

Refers to Grams, M. E. et al. Candidate surrogate end points for ESRD after AKI. J. Am. Soc. Nephrol.

Related Topics

    loading  Loading Related Articles